Suven Life Sciences Limited

Venkata Ramalingayya Grandhi

Venkateswarlu Jasti

Ramakrishna Nirogi

Anil Karbhari Shinde

Abdul Rasheed Mohammed

Pradeep Jayarajan

Gopinadh Bhyrapuneni

Vijay Sidram Benade

Vijay Benade

The present invention relates to new uses of a 5-HTreceptor agonist, specifically Isopropyl-3-{5-[1-(3-methoxypropyl)piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1H-indazole (Compound-1) or a pharmaceutically acceptable salts thereof, for the treatment of dementia due to menopause, senile dementia, cognitive deficits associated with schizophrenia, depression, chemotherapy-induced cognitive impairment, and behavioral and psychological symptoms of dementia such as apathy/indifference, agitation, aggression, depression, anxiety, irritability/lability, dysphoria, aberrant motor behavior, delusions, hallucinations, elation/euphoria, psychosis, disinhibition, sleep and night time behavior disorders or appetite and eating disorders. The present invention further provides use of the 5-HT4 receptor agonist in the manufacture of medicament intended for the treatment of the disorders described herein.

Uses of a 5-HT4 receptor agonist

Growing community of inventors

Hyderabad Telangana, India

Venkata Ramalingayya Grandhi